According to the Hartman Group, heart health is the primary concern for consumers when shopping for groceries. Research from the firm indicates that 55% of U.S. consumers actively seek to limit or reduce saturated fat in their diets, with nearly 40% opting for healthier fats, such as polyunsaturated and monounsaturated fats, instead. Reactions to the FDA’s proposal to eliminate the health claim related to soy protein have been mixed among manufacturers and industry groups. The Soyfoods Association of North America (SANA) expressed concern on Monday, advocating for the retention of the current statement: “25 grams of soy protein a day, as part of a diet low in saturated fat and cholesterol, may reduce the risk of heart disease.” SANA highlighted that numerous scientific studies, both prior to and following the approval of the soy protein health claim in 1999, consistently demonstrate that soy protein can lower LDL cholesterol, justifying the ongoing approval of an unqualified claim. They also pointed out that the FDA’s decision contradicts the stances of 12 other countries that have authorized similar health claims regarding soy protein and heart disease, including Health Canada’s latest approval in 2015.
The Natural Products Association also raised questions about the FDA’s decision. CEO Daniel Fabricant described the move as “somewhat unexpected,” particularly since the agency did not clarify the reasons behind its sudden action. Having previously headed the FDA’s Division of Dietary Supplement Programs, Fabricant likely possesses a solid understanding of the workings of federal regulatory agencies. Meanwhile, the American Heart Association has supported the revocation of the soy protein health claim, arguing that there may be minimal direct health benefits. They noted in 2008 that “the direct cardiovascular health benefit of soy protein or isoflavone supplements is minimal at best.”
If the FDA goes ahead with revoking the unlimited health claim on soy protein products, predicting customer reactions and potential impacts on purchasing decisions becomes challenging. The American Heart Association opposes the agency’s shift to qualified language on affected products, stating that research shows consumers often misunderstand qualified health claims, which are based on limited and inconsistent evidence. Given the proposed rule to revoke the health claim for soybean protein, it is unlikely the FDA will change its course unless a significant number of comments oppose the decision. Stakeholders such as DuPont, which produces isolated soy protein, and Gardein, known for its soy-based protein products, may also voice their concerns. Furthermore, it is improbable that the agency will begin reevaluating its other 11 approved health claims related to food products unless substantial pressure is applied. Only one of these claims pertains to soybean protein, which is currently under review for potential revocation. However, it is worth noting that the FDA has recently approved labeling soybean oil as heart healthy, as it has been found to reduce the risk of coronary heart disease and lower LDL cholesterol.
In the context of health and nutrition, the integration of calcium citrate and vitamin D in the treatment of osteoporosis remains essential. Research has shown that these nutrients play a crucial role in maintaining bone health, which is vital for overall well-being. Ensuring adequate intake of calcium citrate and vitamin D can significantly impact those at risk of osteoporosis, further emphasizing the importance of informed dietary choices in promoting long-term health.